TW257672B - - Google Patents

Info

Publication number
TW257672B
TW257672B TW079104379A TW79104379A TW257672B TW 257672 B TW257672 B TW 257672B TW 079104379 A TW079104379 A TW 079104379A TW 79104379 A TW79104379 A TW 79104379A TW 257672 B TW257672 B TW 257672B
Authority
TW
Taiwan
Prior art keywords
pct
date nov
sec
inclusion compounds
new inclusion
Prior art date
Application number
TW079104379A
Other languages
English (en)
Original Assignee
Rhone Poulenc Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Sante filed Critical Rhone Poulenc Sante
Application granted granted Critical
Publication of TW257672B publication Critical patent/TW257672B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
TW079104379A 1989-05-24 1990-05-30 TW257672B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8906781A FR2647343B1 (fr) 1989-05-24 1989-05-24 Nouvelle forme pharmaceutique poreuse et sa preparation

Publications (1)

Publication Number Publication Date
TW257672B true TW257672B (zh) 1995-09-21

Family

ID=9381955

Family Applications (1)

Application Number Title Priority Date Filing Date
TW079104379A TW257672B (zh) 1989-05-24 1990-05-30

Country Status (24)

Country Link
US (1) US5244881A (zh)
EP (2) EP0399903B1 (zh)
JP (1) JP2948271B2 (zh)
KR (1) KR0163423B1 (zh)
AT (2) ATE98867T1 (zh)
AU (2) AU631888B2 (zh)
CA (2) CA2017355A1 (zh)
DD (1) DD297915A5 (zh)
DE (2) DE69005359T2 (zh)
DK (2) DK0399902T3 (zh)
ES (2) ES2062437T3 (zh)
FI (1) FI103712B (zh)
FR (1) FR2647343B1 (zh)
GR (1) GR3006655T3 (zh)
IE (2) IE64370B1 (zh)
IL (2) IL94459A (zh)
NO (1) NO180517C (zh)
NZ (2) NZ233766A (zh)
PL (1) PL285327A1 (zh)
PT (2) PT94138B (zh)
TW (1) TW257672B (zh)
WO (1) WO1990014089A1 (zh)
YU (1) YU100790A (zh)
ZA (2) ZA903895B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519428B1 (en) * 1991-06-21 2000-09-20 Takeda Chemical Industries, Ltd. Cyclodextrin compositions with fumagillol derivates
EP0651997B1 (en) 1991-12-24 1998-10-28 Yamanouchi Pharmaceutical Co. Ltd. Intrabuccally disintegrating preparation and production thereof
GB9318880D0 (en) * 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
JPH10500982A (ja) * 1994-05-27 1998-01-27 ファーマーク、ネダーランド、ベスローテン、フェンノートシャップ 医薬組成物
JP4563516B2 (ja) * 1997-02-20 2010-10-13 マサチューセッツ インスティテュート オブ テクノロジー 迅速分散性を示す投与剤形、その使用法並びにその製造方法
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
TW527195B (en) 1997-10-09 2003-04-11 Ssp Co Ltd Fast-soluble solid pharmaceutical combinations
IL137550A0 (en) * 1998-02-05 2001-07-24 Novartis Ag Epothilone compositions
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
US6287603B1 (en) * 1999-09-16 2001-09-11 Nestec S.A. Cyclodextrin flavor delivery systems
AU2003201161B2 (en) 2002-01-15 2008-02-28 Ucb Farchim S.A. Formulations
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
EP1487774B1 (en) 2002-02-25 2018-09-19 Diffusion Pharmaceuticals LLC Bipolar trans carotenoid salts and their uses
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
DE10248314A1 (de) * 2002-10-16 2004-04-29 Dr. Suwelack Skin & Health Care Ag Verwendung von Formkörpern zur äußeren Anwendung
FR2876910B1 (fr) * 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
EA017982B1 (ru) 2005-02-24 2013-04-30 ДИФФЬЮЖН ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Фармацевтическая композиция на основе транскаротиноидов и способы лечения опухоли
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
AU2008246305B2 (en) 2007-04-13 2013-03-21 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
JP2009091309A (ja) * 2007-10-10 2009-04-30 Japan Organo Co Ltd バコパモニエラエキスを含有する組成物およびその製造方法ならびに飲食品
JP2011502125A (ja) 2007-10-31 2011-01-20 ディフュージョン・ファーマシューティカルズ・エルエルシー 小分子拡散を促進する新しい種類の治療法
RU2011112926A (ru) * 2008-09-05 2012-10-10 МакНЕЙЛ-ППС, ИНК. (US) Способ изготовления таблеток цетиризина
JP5787884B2 (ja) 2009-06-22 2015-09-30 ディフュージョン・ファーマシューティカルズ・エルエルシー 拡散増強化合物、及びその単独使用又は血栓溶解剤との併用
US8974822B2 (en) 2010-06-02 2015-03-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
RU2013116336A (ru) * 2010-09-13 2014-10-20 Бев-Арэкс, Инк. Водная система доставки лекарств, содержащая маскирующий вкус агент
RU2609198C1 (ru) * 2016-01-25 2017-01-30 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма имипрамина немедленного высвобождения и способ ее получения
KR102489034B1 (ko) 2016-03-24 2023-01-13 디퓨젼 파마슈티컬즈 엘엘씨 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5443570B2 (zh) * 1972-10-27 1979-12-20
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
US4165382A (en) * 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4349472A (en) * 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US4284555A (en) * 1979-04-27 1981-08-18 Schering Corporation 7-Chloro-8(substituted amino carbonyloxy)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4477378A (en) * 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
WO1986003198A1 (en) * 1984-11-27 1986-06-05 Dainippon Pharmaceutical Co., Ltd. 2-(1-piperazinyl)-4-substituted phenylquinoline derivatives, process for their preparation, and medicinal composition containing same
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition

Also Published As

Publication number Publication date
YU100790A (en) 1992-05-28
ZA903895B (en) 1991-03-27
DD297915A5 (de) 1992-01-30
AU631888B2 (en) 1992-12-10
FR2647343B1 (fr) 1994-05-06
WO1990014089A1 (fr) 1990-11-29
IE64370B1 (en) 1995-07-26
EP0399902B1 (fr) 1993-12-22
ES2054289T3 (es) 1994-08-01
IE901821L (en) 1990-11-24
IL94459A (en) 1995-01-24
PL285327A1 (en) 1991-02-11
EP0399903B1 (fr) 1992-12-23
NO180517C (no) 1997-05-07
DE69000641D1 (de) 1993-02-04
IE901862L (en) 1990-11-24
US5244881A (en) 1993-09-14
DK0399902T3 (da) 1994-02-14
NO902280L (no) 1990-11-26
CA2017360A1 (fr) 1990-11-24
FR2647343A1 (fr) 1990-11-30
EP0399903A1 (fr) 1990-11-28
CA2017355A1 (fr) 1990-11-24
ZA903978B (en) 1991-03-27
DE69005359D1 (de) 1994-02-03
AU5582890A (en) 1991-01-10
NZ233766A (en) 1991-08-27
FI902553A0 (fi) 1990-05-23
ATE83663T1 (de) 1993-01-15
AU623779B2 (en) 1992-05-21
DE69005359T2 (de) 1994-05-05
FI103712B1 (fi) 1999-08-31
KR900017570A (ko) 1990-12-19
DK0399903T3 (da) 1993-02-08
IL94460A0 (en) 1991-03-10
JP2948271B2 (ja) 1999-09-13
EP0399902A1 (fr) 1990-11-28
FI103712B (fi) 1999-08-31
PT94138A (pt) 1991-01-08
NO180517B (no) 1997-01-27
PT94139A (pt) 1991-01-08
PT94138B (pt) 1996-12-31
ATE98867T1 (de) 1994-01-15
PT94139B (pt) 1996-12-31
GR3006655T3 (zh) 1993-06-30
NO902280D0 (no) 1990-05-23
AU5743390A (en) 1990-12-18
NZ233784A (en) 1993-04-28
IE63317B1 (en) 1995-04-05
JPH0356412A (ja) 1991-03-12
KR0163423B1 (ko) 1998-12-01
IL94459A0 (en) 1991-03-10
DE69000641T2 (de) 1993-06-09
ES2062437T3 (es) 1994-12-16

Similar Documents

Publication Publication Date Title
TW257672B (zh)
MY101566A (en) Pharmaceutical compositions.
SE9802937D0 (sv) Novel compounds
DE59203694D1 (de) Rollstuhl, insbesondere für querschnittgelähmte menschen.
NO913035D0 (no) (2r)-2-(di(2-propyl)fosfonylmetoksy)-3-p-toluensulfonyloksy-1-trimetylacetoksypropan, fremgangsmaate for fremstilling og anvendelse derav.
EP0670166A3 (en) Pharmaceutical compositions for oral administration.
BG101401A (en) Cisaspide extended release oral compositions
ZA92110B (en) Pharmaceutical compositions.
EP0619744A4 (en) NON-IONIC RADIOGRAPHIC CONTRAST METHODS, COMPOSITIONS AND AGENTS.
ZA927369B (en) Pharmaceutical compositions.
FR2708855B1 (fr) Compositions pharmaceutiques immunoadjuvantes ou immunostimulantes.
GB8918761D0 (en) Substituted 4-azatricyclo(22.3.1.04.9)octacos-18-ene derivate,its preparation and pharmaceutical compositions containing it
GB8918760D0 (en) Substituted 4-azatricyclo(22.3.1.04.9)octacos-18-ene derivate,its preparation and pharmaceutical compositions containing it
GB8918757D0 (en) Substituted 4-azatricyclo(21.3.1.0.4.8)heptacos-17-ene derivate,its preparation and pharmaceutical compositions containing it
GB8918756D0 (en) Substituted 4-azatricyclo(22.3.1.0.4.9)octacos-18-ene derivate,its preparation and pharmaceutical compositions containing it
IT1258818B (it) Composizioni farmaceutiche orali a base di n5-metiltetraidrofolato di calcio
IT8821136A0 (it) Composizioni farmaceutiche per la litolisi di calcoli biliari secondari residui o ricorrenti.